Related Experiment Video
Updated: Oct 4, 2025

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Thoracic SMARCA4-deficient undifferentiated tumor-a case of an aggressive neoplasm-case report
1Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN, USA.
Abstract:
Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) are aggressive neoplasms that most commonly occur in the mediastinum of male smokers. These tumors are characterized by an inactivating mutation of SMARCA4 resulting in loss of expression of brahma-related gene 1 (BRG1). These tumors can have a variable immunophenotype but in general have no or only focal keratin expression and characteristically lack expression of BRG1. Most patients have metastatic disease at time of presentation. Usually SMARCA4-UT progress or recur and the median survival of these patients is only approximately half a year. Preclinical and clinical trials using enhancer of zeste homolog (EZH2) inhibitors are underway to potentially treat this neoplasm. In addition, rare cases of successful treatment with anti-PD-1 inhibitors are described. Here, the case of a 66-year-old male smoker who presents with mediastinal and left suprahilar masses and widespread metastatic disease is reported. A biopsy reveals extensive necrosis and clusters and small sheets of neoplastic epithelioid cells with some exhibiting rhabdoid cytology. The tumor cells lack staining with various keratins and markers of lymphoid, melanocytic, myogenic, or vascular differentiation. Focal expression of CD30 is noted. BRG1 expression is lost in the tumor cells while INI-1 expression is preserved. This tumor is diagnosed as SMARCA4-UT.
Insights
Aggressive thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) are linked to SMARCA4 gene mutations and poor prognosis. This case highlights diagnostic challenges and potential therapeutic avenues like EZH2 and anti-PD-1 inhibitors.
Area of Science:
- Oncology
- Genetics
- Pathology
Background:
- Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) are aggressive neoplasms.
- They are characterized by inactivating mutations in the SMARCA4 gene, leading to loss of brahma-related gene 1 (BRG1) expression.
Observation:
- The case involves a 66-year-old male smoker presenting with mediastinal and suprahilar masses and widespread metastatic disease.
- Biopsy revealed extensive necrosis and neoplastic epithelioid cells with rhabdoid cytology, lacking keratin and other differentiation markers, but with focal CD30 expression.
Findings:
- Tumor cells demonstrated loss of BRG1 expression while preserving INI-1 expression.
- This immunophenotype, combined with clinical presentation, led to the diagnosis of SMARCA4-UT.
Implications:
- SMARCA4-UT typically presents with metastatic disease and has a poor median survival of approximately six months.
- Ongoing clinical trials are investigating EZH2 inhibitors, and rare successful treatments with anti-PD-1 inhibitors offer potential therapeutic strategies.
More Related Videos
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024